Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
| 0.7745 | |
| 0.7862 | |
| - | |
| 0.82 | |
| 0.757 | |
| 0.49-2.894 | |
| 34 748 K | |
| 43 953 K | |
| 2 357 K | |
| -0.24 | |
| -0.063 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
— Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers — FOSTER CITY, Ca...
Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and XTX202, a tumor-activated, beta-gamma IL-2 On track ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
